TY - JOUR
T1 - Acute Pulmonary Exacerbations in Cystic Fibrosis
T2 - A Double-blind Trial of Tobramycin and Placebo Therapy
AU - Wientzen, R.
AU - Prestidge, C. B.
AU - Kramer, R. I.
AU - McCracken, G. H.
AU - Nelson, J. D.
PY - 1980/12
Y1 - 1980/12
N2 - To determine the effect of antimicrobial therapy on acute pulmonary exacerbations in cystic fibrosis, a randomized, double-blind trial of tobramycin and placebo was carried out. Clinical responses were satisfactory in all 11 children given tobramycin and in seven of 11 given placebo. Two patients in the placebo group died. No patient given placebo had improved results on pulmonary function studies, whereas improvement of 15% or more occurred in four of the six patients given tobramycin who could cooperate with the testing. Quantitative cultures of sputum showed a decrease of 1 logarithm or greater in Pseudomonas sp concentrations in six of seven patients in the tobramycin group and in two of eight in the placebo group. No difference in staphylococcal colonization was found. Several features indicate that children with severer disease were randomly assigned to the placebo group; nevertheless, the trend toward improved response in patients given tobramycin suggests that empirical therapy with antibiotics is beneficial for patients with acute pulmonary exacerbations in cystic fibrosis. (Am J Dis Child 134:1134-1138, 1980.
AB - To determine the effect of antimicrobial therapy on acute pulmonary exacerbations in cystic fibrosis, a randomized, double-blind trial of tobramycin and placebo was carried out. Clinical responses were satisfactory in all 11 children given tobramycin and in seven of 11 given placebo. Two patients in the placebo group died. No patient given placebo had improved results on pulmonary function studies, whereas improvement of 15% or more occurred in four of the six patients given tobramycin who could cooperate with the testing. Quantitative cultures of sputum showed a decrease of 1 logarithm or greater in Pseudomonas sp concentrations in six of seven patients in the tobramycin group and in two of eight in the placebo group. No difference in staphylococcal colonization was found. Several features indicate that children with severer disease were randomly assigned to the placebo group; nevertheless, the trend toward improved response in patients given tobramycin suggests that empirical therapy with antibiotics is beneficial for patients with acute pulmonary exacerbations in cystic fibrosis. (Am J Dis Child 134:1134-1138, 1980.
UR - http://www.scopus.com/inward/record.url?scp=0019212226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019212226&partnerID=8YFLogxK
U2 - 10.1001/archpedi.1980.02130240018007
DO - 10.1001/archpedi.1980.02130240018007
M3 - Article
C2 - 7004176
AN - SCOPUS:0019212226
SN - 0096-8994
VL - 134
SP - 1134
EP - 1138
JO - American Journal of Diseases of Children
JF - American Journal of Diseases of Children
IS - 12
ER -